BTAI vs NOC · rev $388.0K vs P/E 17, rev $20.76B
BioXcel Therapeutics Inc (BTAI) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported NOC revenue for 2026-06-30 was $20.76B. Net income was $1.97B. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
BTAI currently screens at market cap $36.1M. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the BTAI and NOC stock pages for the full models.
Not investment advice.